HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $300 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Biogen (NASDAQ:BIIB) and maintained a price target of $300.
October 31, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Biogen, maintaining a $300 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $300 price target by HC Wainwright & Co. suggests a positive outlook for Biogen, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100